P
Paolo Anderlini
Researcher at University of Texas MD Anderson Cancer Center
Publications - 262
Citations - 13614
Paolo Anderlini is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 55, co-authored 256 publications receiving 12853 citations.
Papers
More filters
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti,Brent R. Logan,Stephanie J. Lee,Edmund K. Waller,Daniel J. Weisdorf,John R. Wingard,Corey Cutler,Peter Westervelt,Ann E. Woolfrey,Stephen Couban,Gerhard Ehninger,Laura Johnston,Richard T. Maziarz,Michael A. Pulsipher,David L. Porter,Shin Mineishi,John M. McCarty,Shakila P. Khan,Paolo Anderlini,William I. Bensinger,Susan F. Leitman,Scott D. Rowley,Christopher Bredeson,Shelly L. Carter,Mary M. Horowitz,Dennis L. Confer +25 more
TL;DR: A phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors did not detect significant survival differences, and exploratory analyses of secondary end points indicated that peripheral- Blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduceThe risk of chronic GVHD.
Journal ArticleDOI
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt,Peter F. Thall,Issa F. Khouri,Xuemei Wang,Ira Braunschweig,Cindy Ippolitti,David F. Claxton,Michele L. Donato,J. Bruton,A. Cohen,Marilyn S. Davis,Borje S. Andersson,Paolo Anderlini,James Gajewski,Steven M. Kornblau,Michael Andreeff,Donna Przepiorka,Naoto T. Ueno,Jeffrey J. Molldrem,Richard E. Champlin +19 more
TL;DR: Fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population, according to multivariate analysis.
Journal ArticleDOI
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
Issa F. Khouri,Rima M. Saliba,Sergio Giralt,Ming Sheng Lee,Grace Julia Okoroji,Fredrick B. Hagemeister,Martin Korbling,Anas Younes,Cindy Ippoliti,James Gajewski,Peter McLaughlin,Paolo Anderlini,Michele L. Donato,Fernando Cabanillas,Richard E. Champlin +14 more
TL;DR: Nonablative chemotherapy with fludarabine/cyclophosphamide followed by allogeneic stem cell transplantation is a promising therapy for indolent lymphoma with minimal toxicity and myelosuppression.
Journal ArticleDOI
Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
Martin Korbling,Paolo Anderlini +1 more
TL;DR: The various stem cell sources differ in their reconstitutive and immunogenic characteristics, which are based on the proportion of early pluripotent and self-renewing stem cells to lineage-committed late progenitor cells and on the number and characteristics of accompanying "accessory cells" contained in stem cell allografts.